Long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6months in treatment-experienced people with HIV and detectable viremia in the phase 3b CROWN trial.
|Videos|July 30, 2017
Who Are the Core Partners Involved in the Fast-Track Cities Initiative?
Author(s)Contagion Editorial Staff
Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.
Advertisement
Benjamin Young, MD, PhD, Senior Vice President, Chief Medical Officer, International Association of Providers in AIDS Care, discusses the four partners behind the Fast-Track Cities Initiative.
Interview Transcript (slightly modified for readability)
“There are 4 core partners to the Fast-Track Cities Initiative: IAPAC, the International Association of Providers in AIDS Care, UNAIDS, UN-Habitat, and the [Mairie de Paris] city of Paris. Those 4 partners work together to try to bring together the community leadership, the governmental leadership, and the medical expertise necessary to end the AIDS epidemic.”
Advertisement
Related to this article
Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement